Overview

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, non-randomised, 48 week study of the effect of protease inhibitor (PI) containing and non-PI containing antiretroviral regimens on the expression of adipocyte specific genes, protein levels and cellular structure in HIV-infected individuals, naive to therapy, who are starting therapy for the first time.
Phase:
Phase 4
Details
Lead Sponsor:
Kirby Institute
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
St Vincent's Hospital, Sydney
Treatments:
Abacavir
Amprenavir
Didanosine
Efavirenz
Enfuvirtide
Indinavir
Lamivudine
Nelfinavir
Nevirapine
Ritonavir
Saquinavir
Stavudine
Tenofovir
Tipranavir
Zidovudine